Your browser is no longer supported. Please, upgrade your browser.
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E17.27 EPS (ttm)19.06 Insider Own0.20% Shs Outstand149.70M Perf Week0.86%
Market Cap49.70B Forward P/E15.70 EPS next Y20.97 Insider Trans-3.27% Shs Float149.57M Perf Month-4.79%
Income3.01B PEG- EPS next Q4.25 Inst Own86.80% Short Float1.25% Perf Quarter24.06%
Sales12.60B P/S3.94 EPS this Y-21.10% Inst Trans0.11% Short Ratio0.93 Perf Half Y22.88%
Book/sh71.82 P/B4.58 EPS next Y12.28% ROA7.80% Target Price404.08 Perf Year17.41%
Cash/sh20.20 P/C16.29 EPS next 5Y-8.03% ROE17.90% 52W Range223.25 - 468.55 Perf YTD34.43%
Dividend- P/FCF18.79 EPS past 5Y10.10% ROI19.60% 52W High-29.75% Beta0.40
Dividend %- Quick Ratio1.80 Sales past 5Y4.50% Gross Margin85.50% 52W Low47.44% ATR10.71
Employees9100 Current Ratio2.10 Sales Q/Q-24.60% Oper. Margin17.60% RSI (14)43.90 Volatility2.70% 3.02%
OptionableYes Debt/Eq0.00 EPS Q/Q-68.80% Profit Margin15.20% Rel Volume0.33 Prev Close334.18
ShortableYes LT Debt/Eq0.68 EarningsJul 22 BMO Payout0.00% Avg Volume2.02M Price329.17
Recom2.30 SMA20-3.17% SMA50-2.42% SMA20016.44% Volume655,735 Change-1.50%
Jun-18-21Upgrade Piper Sandler Neutral → Overweight $384 → $450
Jun-14-21Reiterated Truist Buy $458 → $647
Jun-11-21Upgrade Bernstein Mkt Perform → Outperform $500
Jun-10-21Upgrade UBS Neutral → Buy
Jun-08-21Upgrade William Blair Mkt Perform → Outperform
Jun-08-21Upgrade Robert W. Baird Underperform → Neutral $216 → $382
Jun-08-21Upgrade Citigroup Sell → Neutral $200 → $440
Jun-08-21Upgrade Atlantic Equities Underweight → Neutral $415
Jun-08-21Reiterated Stifel Buy $346 → $446
Jun-08-21Reiterated RBC Capital Mkts Sector Perform $259 → $400
Jun-08-21Reiterated Morgan Stanley Overweight $343 → $455
Jun-08-21Reiterated Jefferies Buy $450 → $500
Jun-08-21Reiterated H.C. Wainwright Buy $305 → $452
Jun-08-21Reiterated Barclays Equal Weight $265 → $395
Jun-07-21Upgrade Raymond James Underperform → Mkt Perform
Jun-07-21Upgrade Cowen Market Perform → Outperform $225 → $450
Jun-07-21Upgrade BofA Securities Underperform → Neutral $235 → $400
Feb-05-21Downgrade DZ Bank Buy → Hold $264
Jan-29-21Upgrade Stifel Hold → Buy $258 → $358
Nov-10-20Upgrade DZ Bank Hold → Buy $265
Jul-29-21 06:56PM  
04:30PM  
04:10PM  
07:32AM  
06:25AM  
Jul-28-21 01:51PM  
Jul-27-21 04:19PM  
11:14AM  
06:29AM  
Jul-26-21 04:35PM  
04:10PM  
Jul-25-21 06:00AM  
03:28AM  
Jul-23-21 04:30PM  
Jul-22-21 11:00PM  
09:30PM  
04:10PM  
03:07PM  
02:11PM  
11:03AM  
10:27AM  
09:36AM  
08:25AM  
07:53AM  
07:20AM  
07:11AM  
07:11AM  
07:07AM  
07:06AM  
07:05AM  
06:38AM  
05:48AM  
04:22AM  
Jul-21-21 08:00PM  
03:39PM  
11:49AM  
08:33AM  
08:03AM  
07:18AM  
Jul-20-21 02:45PM  
07:38AM  
Jul-19-21 10:47AM  
10:19AM  
Jul-18-21 09:01AM  
Jul-17-21 07:37AM  
Jul-16-21 05:50PM  
02:31PM  
12:03PM  
10:12AM  
08:25AM  
07:45AM  
07:38AM  
Jul-15-21 08:04PM  
04:35PM  
04:21PM  
04:20PM  
03:23PM  
03:01PM  
02:55PM  
02:27PM  
02:11PM  
01:35PM  
12:42PM  
11:37AM  
10:59AM  
10:51AM  
06:41AM  
Jul-14-21 03:53PM  
03:21PM  
02:54PM  
11:22AM  
08:17AM  
Jul-13-21 12:41PM  
10:21AM  
09:43AM  
06:03AM  
Jul-12-21 09:29PM  
09:07PM  
07:12PM  
07:00PM  
06:09PM  
10:10AM  
06:00AM  
04:41AM  
Jul-09-21 04:25PM  
03:35PM  
02:56PM  
02:34PM  
02:33PM  
02:15PM  
12:14PM  
11:16AM  
10:16AM  
08:21AM  
07:07AM  
Jul-08-21 04:19PM  
04:06PM  
12:35PM  
11:55AM  
11:43AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; and Capsigen Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sandrock AlfredHead of Research & DevelopmentJun 07Sale440.007,6723,375,68010,169Jun 09 07:05 PM
Guindo ChirfiHead of Glob Prod Strat & ComJun 07Sale440.003,0871,358,2802,919Jun 09 07:04 PM
Posner Brian SDirectorJun 04Sale274.1736098,7017,400Jun 07 07:02 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.004,454019,715Feb 17 05:01 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0016,289060,194Feb 17 05:03 PM
Kramer RobinSVP, Chief Accounting OfficerFeb 12Option Exercise0.003330706Feb 17 04:59 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.003,15606,946Feb 17 04:58 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.002,92309,288Feb 17 04:56 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,57304,765Feb 17 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.004,355043,509Feb 17 04:52 PM
Mantas Jesus BDirectorFeb 09Buy267.00898239,7662,943Feb 10 04:31 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00740395Dec 07 09:08 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0048104,004Dec 03 05:41 PM
Vounatsos MichelChief Executive OfficerNov 30Buy241.313,100748,04734,810Dec 01 04:57 PM
Sandrock AlfredEVP, Research & DevelopmentNov 04Sale350.001,500525,00013,066Nov 06 09:39 PM
Gregory GingerEVP, Human ResourcesJul 31Option Exercise0.0021204,786Aug 04 04:12 PM